The efficacy of adjuvant radioactive iodine after reoperation in patients with persistent or recurrent differentiated thyroid cancer: a systematic review.
Jaivikash RaghupathyBenjamin Kye Jyn TanHarris J J M D SongAlys Z Q ChiaYi Zhao TanSamantha Peiling YangRajeev ParameswaranPublished in: Langenbeck's archives of surgery (2023)
Adjuvant RAI after reoperation in recurrent DTC was not associated with improved cancer or treatment-related outcomes. However, as the included studies were of inadequate quality, there is an urgent need for randomized trials and well-analyzed cohort studies. Physicians should exercise clinical judgment to prescribe adjuvant RAI for only selected, high-risk patients.
Keyphrases
- early stage
- end stage renal disease
- ejection fraction
- primary care
- chronic kidney disease
- newly diagnosed
- papillary thyroid
- prognostic factors
- high intensity
- peritoneal dialysis
- physical activity
- magnetic resonance imaging
- squamous cell carcinoma
- type diabetes
- computed tomography
- case control
- insulin resistance
- replacement therapy
- drug induced
- contrast enhanced